| Antiretroviral drug exposure in the female genital tract: implications for oral pre-and post-exposure prophylaxis JB Dumond, RF Yeh, KB Patterson, AH Corbett, BH Jung, NL Rezk, ... Aids 21 (14), 1899-1907, 2007 | 231 | 2007 |
| Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women JB Dumond, KB Patterson, AL Pecha, RE Werner, E Andrews, B Damle, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 51 (5), 546-553, 2009 | 153 | 2009 |
| Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men KC Brown, KB Patterson, SA Malone, NJ Shaheen, HM Asher Prince, ... Journal of Infectious Diseases 203 (10), 1484-1490, 2011 | 108 | 2011 |
| Pre-exposure prophylaxis for HIV prevention: how to predict success ADM Kashuba, KB Patterson, JB Dumond, MS Cohen The lancet 379 (9835), 2409-2411, 2012 | 97 | 2012 |
| A Phenotype–Genotype Approach to Predicting CYP450 and P‐Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir JB Dumond, M Vourvahis, NL Rezk, KB Patterson, HC Tien, N White, ... Clinical Pharmacology & Therapeutics 87 (6), 735-742, 2010 | 77 | 2010 |
| Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women RF Yeh, NL Rezk, ADM Kashuba, JB Dumond, HL Tappouni, HC Tien, ... Antimicrobial agents and chemotherapy 53 (6), 2367-2374, 2009 | 67 | 2009 |
| Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing BN Greener, KB Patterson, HMA Prince, CS Sykes, JL Adams, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 64 (1), 39-44, 2013 | 65 | 2013 |
| Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women JL Adams, KB Patterson, HMA Prince, C Sykes, BN Greener, JB Dumond, ... Antiviral therapy 18 (8), 1005-1013, 2013 | 50 | 2013 |
| Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men JB Dumond, YS Reddy, L Troiani, JF Rodriguez, AS Bridges, SA Fiscus, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 48 (2), 156-162, 2008 | 50 | 2008 |
| Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines KB Patterson, JB Dumond, HA Prince, AJ Jenkins, KK Scarsi, R Wang, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 63 (1), 51-58, 2013 | 46 | 2013 |
| Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women EJ Geller, AK Crane, EC Wells, BL Robinson, ML Jannelli, ... Clinical drug investigation 32, 697-705, 2012 | 46 | 2012 |
| Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial EJ Geller, JB Dumond, JM Bowling, CM Khandelwal, JM Wu, ... Urogynecology 23 (2), 118-123, 2017 | 44 | 2017 |
| Pharmacokinetics of two common antiretroviral regimens in older HIV‐infected patients: a pilot study JB Dumond, JL Adams, HMA Prince, RL Kendrick, R Wang, SH Jennings, ... HIV medicine 14 (7), 401-409, 2013 | 35 | 2013 |
| Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women JB Dumond, MR Nicol, RN Kendrick, SM Garonzik, KB Patterson, ... Clinical pharmacokinetics 51, 809-822, 2012 | 31 | 2012 |
| Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers A Kwara, KT Tashima, JB Dumond, P Poethke, J Kurpewski, ... Antimicrobial agents and chemotherapy 55 (7), 3527-3533, 2011 | 27 | 2011 |
| First dose and steady-state genital tract pharmacokinetics of ten antiretroviral drugs in HIV-infected women: implications for pre-and post-exposure prophylaxis J Dumond, R Yeh, K Patterson, A Corbett, B Jung, N Rezk, A Bridges, ... 13th Conference on Retroviruses and Opportunistic Infections, 2006 | 21 | 2006 |
| A pharmacokinetic/pharmacodynamic model to predict effective HIV prophylaxis dosing strategies for people who inject drugs KL Garrett, J Chen, BM Maas, ML Cottrell, HA Prince, C Sykes, ... Journal of Pharmacology and Experimental Therapeutics 367 (2), 245-251, 2018 | 20 | 2018 |
| Maraviroc (MVC) pharmacokinetics (PK) in blood plasma (BP), genital tract (GT) fluid and tissue in healthy female volunteers J Dumond, K Patterson, A Pecha, R Werner, E Andrews, B Damle, ... 15th Conference on Retroviruses and Opportunistic Infections, 3-6, 2008 | 18* | 2008 |
| Effects of tipranavir/ritonavir (TPV/r) on the activity of hepatic and intestinal cytochrome P450 3A4/5 and P-glycoprotein (P-gp): implications for drug interactions M Vourvahis, J Dumond, K Patterson, N Rezk, N White, S Jennings, ... 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles …, 2007 | 18 | 2007 |
| Population modeling highlights drug disposition differences between tenofovir alafenamide and tenofovir disoproxil fumarate in the blood and semen SA Greene, J Chen, HMA Prince, C Sykes, AP Schauer, K Blake, ... Clinical Pharmacology & Therapeutics 106 (4), 821-830, 2019 | 17 | 2019 |
Angela DM KashubaUNC Eshelman School of Pharmacy在 unc.edu 的电子邮件经过验证
